Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. (Record no. 200)

MARC details
000 -LEADER
fixed length control field 02943nam a22003497a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 221027s20222022 xxu||||| |||| 00| 0 eng d
024 ## - OTHER STANDARD IDENTIFIER
Standard number or code 10.1002/bdr2.2091 [doi]
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 36177676
245 ## - TITLE STATEMENT
Title Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry.
251 ## - Source
Source Birth Defects Research. 2022 Sep 30
252 ## - Abbreviated Source
Abbreviated source Birth Defects Res Part A Clin Mol Teratol. 2022 Sep 30
253 ## - Journal Name
Journal name Birth defects research
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2022
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2023
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Publication date 2022 Sep 30
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE]
Publication status aheadofprint
266 ## - Date added to catalog
Date added to catalog 2022-10-27
520 ## - SUMMARY, ETC.
Abstract BACKGROUND: Belimumab is approved for active, autoantibody-positive systemic lupus erythematosus (SLE) and lupus nephritis, but limited data exist regarding its use in pregnancy. The Belimumab Pregnancy Registry (BPR, GSK Study BEL114256; NCT01532310) was created to evaluate pregnancy and infant outcomes following belimumab exposure.
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: Low recruitment numbers for the BPR and incomplete information limit the conclusions regarding belimumab exposure during pregnancy. There was no pattern or common mechanism of birth defects associated with belimumab within the BPR data. Copyright © 2022 GSK. Birth Defects Research published by Wiley Periodicals LLC.
520 ## - SUMMARY, ETC.
Abstract METHODS: Individuals with SLE exposed to belimumab from 4 months before and/or during pregnancy can enroll into the BPR. The primary outcome is major birth defects; secondary outcomes include miscarriages, stillbirths, elective termination, pre-term birth, neonatal death, small for gestational age, and adverse infant outcomes during the first year of life. Belimumab exposure timing, concomitant medications, and other potential confounding factors are also collected. Data up to March 8, 2021, are reported descriptively.
520 ## - SUMMARY, ETC.
Abstract RESULTS: From an expected sample size target of 500 prospective pregnancies with a known outcome, only 55 were enrolled in the study. Among these, two pregnancy losses and 53 pregnancies with a live birth outcome were reported. Ten of the 53 live birth pregnancies resulted in a major birth defect. Ten pregnancies were enrolled after the pregnancy outcome occurred and were examined retrospectively (four live births with no defects, four miscarriages, and two elective terminations). There was no indication or pattern of birth defects associated with belimumab.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Obstetrics and Gynecology/ Maternal-Fetal Medicine
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Landy, Helain
790 ## - Authors
All authors Covington D, Gemzoe K, Gilbride J, Juliao P, Landy H, Liu A, Marino R, Meizlik P, Moody MA, Moore T, Petri M, Pimenta JM, Tilson H, Wurst K
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1002/bdr2.2091">https://dx.doi.org/10.1002/bdr2.2091</a>
Public note https://dx.doi.org/10.1002/bdr2.2091
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 10/27/2022   36177676 36177676 10/27/2022 10/27/2022 Journal Article

Powered by Koha